Received on 21.05.2023 Modified on 27.09.2023

Research J. Pharm. and Tech 2024; 17(2):927-933.

DOI: 10.52711/0974-360X.2024.00144

INTRODUCTION:

Tobacco use addiction is a significant barrier that hinders individuals, including those diagnosed with cancer, cardiovascular disease (CVD), respiratory disorder, and other diseases, from successfully quitting tobacco use. Nicotine, a highly addictive substance found in tobacco products, leads to the development of dependence and makes quitting smoking a challenging endeavor¹. This dependence on nicotine often becomes a major reason why patients with cancer and other health conditions struggle to quit tobacco use², despite being aware of the detrimental effects on their health^3-6. For patients with cancer and CVD, tobacco use addiction poses additional risks and complexities. The adverse health consequences of continued tobacco use can compromise their treatment outcomes and overall prognosis. Smoking during cancer treatment has been associated with reduced treatment effectiveness, increased risk of complications, poorer response to therapy, and heightened mortality rates⁷. Despite these grave risks, many patients find it incredibly difficult to break free from the grip of nicotine addiction^8-10. Moreover, tobacco use addiction extends beyond cancer and CVD patients and affects individuals with various other diseases as well^11,12. Those living with chronic conditions such as cardiovascular diseases, respiratory disorders, and psychiatric illnesses often struggle to quit tobacco use due to the powerful hold of nicotine addiction. Nicotine's impact on the brain's reward system and withdrawal symptoms experienced when attempting to quit make it a formidable challenge for patients to overcome^8-10,13,14.

To address this issue, healthcare providers play a crucial role in supporting patients with cancer and other diseases to quit tobacco use. Tailored interventions, such as medication-assisted treatments and behavioral therapies, should be implemented to address both the physical and psychological aspects of tobacco use addiction^15-17. Providing education, counseling, and ongoing support is vital in helping patients understand the risks of tobacco use and empowering them to overcome nicotine addiction^10,14,18,19.

By acknowledging tobacco use addiction as a major obstacle in quitting tobacco use among patients with cancer and other diseases, healthcare providers can offer tailored interventions and support systems to enhance cessation efforts. By addressing nicotine addiction alongside the treatment of the underlying condition, healthcare professionals can significantly improve patient outcomes and overall well-being.

Background About Tobacco Use Hazards and Nicotine Addition:

Tobacco use, production, and consumption persist globally, with approximately 1.5 billion smokers^9,20,21. Alarmingly, around half of this population is expected to succumb to illnesses attributed to smoking. Smoking is identified as a primary, preventable factor contributing to various cancers, cardiovascular diseases, strokes, pregnancy complications, and chronic obstructive pulmonary disease. Significantly, quitting smoking has proven to diminish the incidence and mortality rates associated with these health conditions^9,20,22.

Roughly one-third of the global adult male population engages in smoking, with smoking-related diseases claiming the lives of 1 in 10 adults worldwide. Shockingly, every eight seconds witnesses the loss of someone to tobacco use, and if current trends persist, smoking is projected to be responsible for one in six global deaths. While smoking prevalence declines in developed nations, it is on the ascent in the developing world, with tobacco consumption rising by 3.4% annually^19-21. This global health challenge manifests starkly in the United States, where tobacco use remains the most preventable cause of death, resulting in over 435,000 deaths annually. Of concern, 45 million (21%) adult Americans continue to smoke. Despite widespread awareness of the health risks, a disheartening daily average of approximately 1,200 children and adolescents initiate cigarette smoking^23-25. Even individuals with severe medical conditions, such as acute coronary syndrome or asthma, struggle to quit smoking. In 2015, merely 4 to 7 percent of 19million American adults attempting cessation succeeded, and the unfortunate reality persists that 80% of smokers attempting self-quit relapse within the first month of abstinence, with only 3% remaining abstinent at the six-month mark^23-26. These challenges in quitting may be attributed to tobacco use addiction and insufficient motivating factors, including an individual's confidence, readiness, and self-efficacy to quit tobacco use.^{10,14,21,27,28}

Tobacco use addiction is a multifaceted phenomenon governed by diverse neurobiological mechanisms. Upon entering the body through smoking or alternative forms, nicotine swiftly accesses the brain, binding to specific receptors called nicotinic acetylcholine receptors (nAChRs). Predominantly situated in reward-associated regions like the ventral tegmental area (VTA) and the nucleus accumbens (NAc), these receptors play a pivotal role in motivation and reinforcement. Nicotine's interaction with nAChRs induces the release of neurotransmitters—dopamine, serotonin, and norepinephrine—contributing to the rewarding effects of nicotine.^8,28-30 Repeated nicotine exposure induces neuroadaptive changes in the brain, sensitizing the reward circuitry to nicotine. This involves long-term potentiation (LTP) in synaptic connections, particularly in the mesolimbic dopamine pathway. Elevated dopamine release reinforces the association between smoking and pleasurable feelings, establishing it as a highly rewarding behavior. Chronic nicotine exposure prompts downregulation of nAChRs, diminishing their sensitivity to nicotine^8,29,30. This desensitization results in reduced pleasurable effects, compelling individuals to seek higher doses for equivalent rewards. NAc also experiences alterations in neurotransmitter systems—glutamate, GABA, and endogenous opioids—further contributing to the onset and perpetuation of tobacco use addiction.^8,10,29,30

Comprehending the neurobiology of tobacco use addiction is essential for formulating impactful treatments and interventions to facilitate smoking cessation. Focusing on the distinct neural pathways and receptors implicated in nicotine addiction enables the creation of medications and behavioral therapies that target the fundamental mechanisms of dependence. Furthermore, delving into the intricate interaction between nicotine and the brain provides insights that can inform the exploration of alternative strategies for both smoking cessation and preventing addiction.^{8,10,14,29,30}

Study Purpose:

This study is designed to briefly explore the multifaceted landscape of tobacco use hazards and nicotine addiction. It delves into the adverse health effects associated with tobacco use, emphasizing the intricate neurobiological mechanisms underlying nicotine dependence and their broader implications for overall health. The evaluation extends to preventive and control strategies, scrutinizing existing measures to curb tobacco initiation and prevalence, with a particular focus on interventions targeting addiction. Additionally, the study investigates various treatment approaches, ranging from pharmacological interventions like nicotine replacement therapy to behavioral therapies, assessing their individual and combined effectiveness. By exploring the research implications, the study aims to unveil insights into the neurobiology of nicotine dependence, providing a foundation for targeted interventions and guiding future research directions. The ultimate goal is to furnish healthcare providers with practical recommendations, encouraging discussions on the neurobiology of nicotine addiction, proposing personalized treatment approaches based on individual neurobiological profiles, and underscoring the significance of comprehensive strategies addressing both the physical and psychological dimensions of nicotine addiction. In pursuing these objectives, the study seeks to contribute substantively to the understanding of tobacco use addiction, thereby informing and enhancing preventive measures and treatment strategies.

Prevention, Control, and Treatment of Tobacco Use:

Prevention and Control of Tobacco use addiction:

The widespread acceptance of tobacco use as a significant contributor to severe diseases and global mortality is unequivocal. Recent research underscores the perils of smoking and its association with numerous health conditions. The degree of tobacco use addiction hinges on several factors, including the age of initiation, the form of tobacco consumption, daily cigarette intake, and the duration of tobacco use. Various risk factors, spanning psychosocial, environmental, and economic domains, contribute to nicotine addiction, posing risks to both individual smokers and society at large. Many of these risk factors are modifiable, highlighting the importance of understanding the etiological factors associated with tobacco use addiction and the neurobiology of nicotine. This knowledge forms the foundational basis for comprehending and addressing the prevention, control, and treatment of tobacco use addiction.^9,10,31,32

Health institutions and government agencies play a pivotal role in collaborative efforts aimed at controlling tobacco use and fostering communities that are free from the adverse effects of smoking. One significant aspect of this collaboration involves the establishment of smoking cessation programs and policies. These initiatives are designed not only to assist individuals in quitting smoking but also to safeguard the broader population from the health hazards associated with tobacco use.The nature and scope of smoking cessation programs and policies may vary from one country to another.^9,20,21 The World Health Organization (WHO) Tobacco Convention serves as a critical framework that many nations leverage to legally counteract the tobacco industry's aggressive endeavors to recruit new smokers. This international treaty, officially known as the WHO Framework Convention on Tobacco Control (FCTC), provides a comprehensive set of guidelines and measures to address the global tobacco epidemic.Within the context of these collaborative efforts, health institutions often implement evidence-based strategies to promote smoking cessation. These strategies may include public awareness campaigns, access to smoking cessation aids such as nicotine replacement therapy, counseling services, and support groups. Additionally, policies are enacted to regulate tobacco advertising, enhance warning labels on tobacco products, and establish smoke-free areas to reduce secondhand smoke exposure. The collaboration between health institutions and government agencies is crucial in not only addressing the immediate health concerns associated with tobacco use but also in preventing the initiation of smoking, particularly among vulnerable populations such as youth. By adopting and implementing measures outlined in international conventions like the WHO FCTC, countries can strengthen their resolve against the tobacco industry's influence and work collectively towards creating healthier, tobacco-free communities.^9,20,21

Numerous countries commonly implement regulations for the control of tobacco, incorporating measures such as increasing cigarette taxes, enforcing restrictions on smoking in public spaces and on public transportation, prohibiting tobacco advertising, limiting the sale of tobacco products to minors, and mandating warning labels about the health risks associated with nicotine addiction on tobacco packaging. Violations of these regulations are subject to penalties. Complementary to these regulatory efforts, many initiatives focusing on smoking cessation have been launched. These programs employ diverse media channels, including television ads, radio broadcasts, official newspapers, billboards, and publications, to combat tobacco use, raise awareness about the dangers of smoking and tobacco addiction, and assist individuals in quitting smoking.^20,21,33,34

Treatment of Tobacco use addiction:

The treatment of tobacco use addiction encompasses a diverse array of strategies, giving equal emphasis to both pharmacological and non-pharmacological interventions, particularly the enhancement of self-efficacy, emphasizing health education programs, psychological counseling, and psychosocial support.^1,10,14,28

A. Pharmacological treatment of tobacco use addiction:

A central pharmacological approach is Nicotine Replacement Therapy (NRT), which involves the controlled administration of nicotine through patches, gum, lozenges, nasal sprays, or inhalers to alleviate withdrawal symptoms and cravings. Prescription medications such as Bupropion, an antidepressant, and varenicline, a nicotine receptor blocker, play a crucial role in reducing cravings and withdrawal symptoms. Several medications, including five NRTs and two non-NRTs, have received approval from the US FDA, as identified in the literature. NRTs aim to diminish nicotine delivery speed, reinforcing abstinence and minimizing tobacco toxicity. Non-NRTs like Bupropion and Nortriptyline function as reuptake inhibitors^10,14,28. Moreover, Varenicline, a recent addition, acts on specific receptors, providing an effective tool for quitting tobacco use and preventing relapse.^10,21,35

A multitude of studies consistently underscores the effectiveness of Nicotine Replacement Therapy (NRT) in facilitating smoking cessation. Numerous investigations, establishing NRT as a first-line medication, affirm that its diverse formulations significantly enhance the likelihood of quitting smoking. NRT's efficacy lies in its capacity to relieve withdrawal symptoms, effectively manage cravings, and mitigate the reinforcing effects of nicotine. NRT offers a range of formulations tailored to individual preferences: 1) Nicotine Gum provides on-demand relief mimicking the oral fixation associated with smoking, 2) Nicotine Inhaler aids in transitioning to a smoke-free life by replicating smoking behavior, 3) Nicotine Lozenges allow discreet and portable gradual nicotine release for effective craving management, 4) Nicotine Nasal Spray is rapid-acting, suitable for those with intense cravings, and 5) Nicotine Patch ensures a steady, long-acting nicotine release, minimizing the need for frequent dosing^6,31,36. NRT functions by administering controlled nicotine doses, alleviating withdrawal symptoms linked to quitting smoking. This decouples nicotine intake from harmful tobacco toxins, enabling individuals to gradually reduce nicotine dependence. The diverse formulations address the multifaceted nature of addiction, encompassing both physical and behavioral aspects. While generally well-tolerated, NRT requires careful consideration, with potential side effects such as skin irritation, throat or mouth irritation, and digestive discomfort to be weighed against individual health conditions and preferences. Pregnant individuals must consult healthcare providers due to potential risks^6,31,36. The literature overwhelmingly supports NRT's efficacy as a pivotal component in treating tobacco use addiction. With flexibility, diverse formulations, and an understanding of addiction nuances, NRT empowers individuals to navigate the challenging journey to quit smoking successfully^10,28,30. Health professionals are encouraged to persist in integrating NRT into comprehensive smoking cessation programs, prioritizing personalized approaches for optimal outcomes. Future research should focus on refining NRT utilization and exploring potential advancements in nicotine addiction treatment strategies.^10,14,30

The emergence of Varenicline represents a significant advancement in pharmacotherapy for tobacco use addiction. As a specific α4 β2 nicotinic receptor partial agonist, Varenicline operates on a dual mechanism by stimulating dopamine release while concurrently blocking nicotine receptors. This distinctive pharmacological action positions it as a novel and targeted intervention in the treatment landscape. Varenicline aims to reduce both craving and withdrawal symptoms associated with nicotine dependence. This mechanism is particularly valuable during the critical phase of smoking cessation, as individuals often grapple with intense urges to smoke and the discomfort of withdrawal^10,30,35.The literature underscores the importance of considering Varenicline as part of a comprehensive approach to tobacco use cessation. While its efficacy is well-established, it is also essential to tailor treatment strategies to individual needs, considering factors such as medical history, concurrent medications, and potential side effects.Continued research in this area remains crucial to further delineate the long-term outcomes, potential side effects, and optimal utilization of Varenicline in diverse populations. As the field of pharmacotherapy for tobacco use evolves, the integration of novel agents like Varenicline holds promise for enhancing the efficacy of smoking cessation interventions and contributing to public health efforts to reduce tobacco-related morbidity and mortality ^10,28,30.

Nicotine vaccines, designed to elicit an immune response against nicotine, show promise in curbing tobacco use addiction by hindering its access to the brain. Ongoing trials reveal reduced nicotine distribution in animal models, hinting at efficacy. Concurrently, clinical tests on a selective Cannabinoid CB1 receptor antagonist demonstrate potential in mitigating nicotine's effects, blocking dopamine release in reward-associated brain regions. These innovations signify strides in understanding nicotine addiction's neurobiology, aiming to disrupt its rewarding effects. Preliminary findings suggest a breakthrough in pharmacological interventions, offering targeted strategies for smoking cessation. As research progresses, exploration of long-term effects and safety profiles is crucial for comprehensive treatment options^1,2,10.

B. Non-pharmacological treatment of tobacco use addiction:

The literature review has highlighted the significance of enhancing self-efficacy among tobacco users, emphasizing health education programs, psychological counseling, cognitive-behavioral therapy (CBT), and psychosocial support as crucial elements in the successful treatment of tobacco use addiction. These non-pharmacological interventions are recognized for their effectiveness in addressing the multifaceted nature of nicotine dependence^1,2,10,14,30. The following section briefly explores and discusses these treatments, shedding light on their roles in supporting individuals striving to overcome tobacco addiction:

Improving self-efficacy:

Improving tobacco users' self-efficacy is integral to non-pharmacological tobacco addiction treatment. It involves fostering an individual's belief in successfully quitting smoking. Strategies include behavioral counseling, where therapists collaborate to identify triggers and set realistic goals, instilling a sense of control. Breaking cessation into achievable goals boosts self-efficacy, reinforced by accomplishments. Social support networks offer encouragement and motivation, while education on health benefits empowers individuals. Mindfulness and stress management equip users with coping tools, and problem-solving skills enhance confidence. Continuous monitoring and positive feedback sustain motivation, and visualizing success reinforces the belief in overcoming addiction, collectively enhancing self-efficacy in the journey to quit smoking.

Effectiveness of Counseling:

Psychological counseling plays a crucial role in supporting individuals on their journey to quit smoking. The literature consistently highlights the effectiveness of counseling in promoting smoking cessation. Educational interventions that focus on informing smokers about the benefits of quitting, problem-solving skills, and providing cognitive-behavioral therapy contribute significantly to motivating tobacco users to quit.

Cognitive-Behavioral Therapy (CBT):

Cognitive-behavioral therapy is a cornerstone in the psychological treatment of tobacco use addiction. CBT targets the thoughts, feelings, and behaviors associated with smoking, aiming to modify patterns that contribute to nicotine dependence. By addressing the underlying cognitive processes, CBT equips individuals with coping mechanisms, stress management skills, and strategies to navigate triggers, reinforcing their commitment to smoking cessation.

Psychosocial Support:

Psychosocial support, encompassing social networks, family involvement, and community engagement, has proven instrumental in the cessation process. The encouragement and understanding provided by a supportive social environment can significantly enhance an individual's motivation to quit and maintain abstinence.

Referral to Specialists and Quit Lines:

To optimize the benefits of counseling, referral mechanisms play a crucial role. When smoking cessation specialists are not readily available, referring tobacco users to specialists or utilizing telephone quit lines becomes an important strategy. These resources offer expert guidance, personalized counseling, and support, further augmenting the efficacy of the treatment plan.

Future Directions:

While the literature provides robust support for the effectiveness of health education programs, psychological counseling, CBT, and psychosocial support, ongoing research is essential to refine and tailor these interventions. Exploring the impact of cultural nuances, assessing long-term outcomes, and integrating technology-driven solutions can contribute to the evolution of comprehensive and accessible treatment modalities for tobacco use addiction^2,10,14.

Research implications and recommendations:

The extensive review of literature on the neurobiology of tobacco use addiction and its implications for treatment carries substantial research insights and recommendations for healthcare providers. The study underscores the importance of grasping the neurobiological mechanisms that underlie nicotine addiction to enhance both clinical practices and patient care^9,10,13.

This knowledge can be harnessed by healthcare providers to formulate more effective strategies for tobacco use treatment and smoking cessation interventions. Firstly, healthcare providers are encouraged to integrate neurobiological aspects into patient consultations, educating individuals about nicotine's addictive nature and its impact on the brain. This approach aims to deepen the understanding of challenges associated with quitting smoking, potentially increasing patient motivation and treatment engagement for more successful outcomes. Furthermore, healthcare providers should adopt a personalized treatment approach, considering the unique neurobiological profiles of each patient. Recognizing individual variations in neurobiological factors influencing nicotine addiction, such as genetic predispositions or neurotransmitter pathway differences, can help tailor interventions more effectively. This, in turn, improves treatment efficacy. The research also emphasizes the significance of comprehensive and multidimensional treatment approaches. Healthcare providers are urged to promote a combination of pharmacological interventions, like nicotine replacement therapy or prescription medications, alongside behavioral therapies and counseling. This integrated strategy addresses both the physical and psychological aspects of nicotine addiction, offering individuals a greater likelihood of successful smoking cessation and long-term recovery.

In conclusion, healthcare providers are advised to leverage the insights gleaned from the neurobiology of tobacco use addiction to enhance their practice. By incorporating this knowledge into patient consultations, personalizing treatment plans, and adopting comprehensive approaches, providers can make substantial contributions to improving outcomes in tobacco use treatment and supporting individuals on their journey toward smoking cessation.

CONCLUSION:

The literature review on the neurobiology of tobacco use addiction illuminates the intricate relationship between neurobiology and addiction, unveiling the complex neural pathways underpinning nicotine addiction and elucidating its physiological and psychological dimensions. This understanding of the neurobiological basis presents an opportunity for healthcare providers to refine their approach to tobacco use treatment and smoking cessation. The research suggests that discussing the neurobiology of nicotine addiction with patients can elevate awareness and motivation to quit smoking. Personalized interventions based on individual neurobiological profiles are recommended for heightened efficacy. The study underscores the significance of comprehensive treatment strategies integrating pharmacological interventions and behavioral therapies to address both physical and psychological facets of nicotine addiction. By incorporating these insights, healthcare providers can bolster individuals in their smoking cessation journey, fostering improved overall well-being. This research contributes to evidence-based practices, guiding healthcare providers to enhance success rates in tobacco use treatment and, ultimately, positively impacting public health by reducing tobacco-related morbidity and mortality.

ACKNOWLEDGEMENT:

This study is supported via funding from Prince Sattam Bin Abdulziz University project number (PSAU/2023/R/1445).

REFERENCES:

1. Baker TB, Mermelstein R, Collins LM, Piper ME, Jorenby DE, Smith SS, et al. New methods for tobacco dependence treatment research. Annals of Behavioral Medicine. 2011; 41(2): 192-207. https://doi.org/10.1007/s12160-010-9252-y

2. Rose JE. The motivational impact of nicotine and its role in tobacco use. New findings on nicotine addiction and treatment. Nebraska Symposium on Motivation. 2009: 131-41. https://doi.org/10.1007/978-0-387-78748-0_8.

3. Sara C, Ouidad A, Islam B, Yousra GI, Samir D. The effect of Chronic Tobacco smoking on Atherogenic index and Cardiovascular diseases risk in El-Oued (Algeria) Men. 2020 https://doi.org/10.5958/0974-4150.2020.00086.3.

4. Jadhav RP, Kengar MD, Nikam NR, Bhutkar MA. Tobacco Cancer: A Review. Asian Journal of Research in Pharmaceutical Science. 2019; 9(4): 276-81. https://doi.org/10.5958/2231-5659.2019.00044.4

5. Sahoo P. A Comparative Study on Health Problem (Oral Problems) with Associated Selected Factors Related to Smokeless Tobacco Consumption among Rural and Urban Women of Selected Area of Nabarangpur District, Odissa. Asian Journal of Nursing Education and Research. 2013; 3(2): 107-10. Available on: https://www.indianjournals.com/ijor.aspx?target=ijor:ajner&volume=3&issue=2&article=013.

6. Noor S. Tobacco associated malignant and non-malignant lesions of the oral cavity. Research Journal of Pharmacy and Technology. 2015; 8(8): 1063-7. https://doi.org/10.5958/0974-360X.2015.00183.3.

7. Kudari A. Smoking Kills: Help an Individual in Quit Smoking; Nursing Consideration. Asian Journal of Nursing Education and Research. 2017; 7(3): 441-6. https://doi.org/10.5958/2349-2996.2017.00086.6

8. Benowitz NL. Neurobiology of nicotine addiction: implications for smoking cessation treatment. The American journal of medicine. 2008; 121(4): S3-S10. https://doi.org/10.1016/j.amjmed.2008.01.015

9. Health UDo, Services H. The health consequences of smoking—50 years of progress: a report of the Surgeon General. 2014 https://doi.org/10.1037/e510072014-001

10. Elshatarat RA, Saleh ZT. Treatment of nicotine dependence. Journal of Drug Addiction, Education, and Eradication. 2015;11(3/4): 213. https://doi.org/100.1177/2010105816667137

11. Koli MR, Girase CJ, Patil PA. Scientific approach to treat tobacco addiction-a review. Research Journal of Pharmacognosy and Phytochemistry. 2020; 12(4): 231-4. https://doi.org/10.5958/0975-4385.2020.00039.4.

12. Khandakar AM. Smoking and Chewing Tobacco: Obstacle towards Sustainable Development. Research Journal of Humanities and Social Sciences. 2013;4(4):603-7. Available on: https://rjhssonline.com/AbstractView.aspx?PID=2013-4-4-29.

13. Fiore MC, Jaen CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and dependence: 2008 update US Public Health Service Clinical Practice Guideline executive summary. Respiratory care. 2008; 53(9): 1217-22. https://doi.org/10.1037/e481882008-001

14. Elshatarat RA, Yacoub MI, Khraim FM, Saleh ZT, Afaneh TR. Self-efficacy in treating tobacco use: A review article. Proceedings of Singapore Healthcare. 2016; 25(4): 243-8. https://doi.org/10.1177/2010105816667137

15. Patel V. A study to assess the effectiveness of structured programme on knoweldge regarding tobacco consumption and its hazard among adolescents group in selected school of Visnagar City. Asian Journal of Nursing Education and Research. 2021; 11(1): 79-82. https://doi.org/10.5958/2349-2996.2021.00020.3.

16. Parel JT, Khakha DC, Balhara Y. Do psychiatric nurses have favourable knowledge and attitude towards tobacco prevention among their patients? A cross-sectional study from national capital of India. Asian Journal of Nursing Education and Research. 2018; 8(1):1-4. https://doi.org/10.5958/2349-2996.2018.00001.0.

17. Reshma K, Bennichan S, Sreelakshmi S, Julius V. A study to assess the knowledge regarding adverse effect of tobacco use among adolescent boys in selected areas of Kerala. Asian Journal of Nursing Education and Research. 2022; 12(1): 128-31. https://doi.org/10.52711/2349-2996.2022.00027.

18. Jaén CR, Benowitz NL, Curry SJ, Parsippany N, Kottke TE, Mermelstein RJ, et al. A clinical practice guideline for treating tobacco use and dependence: 2008 update. Am J Prev Med. 2008; 35(2): 158-76. https://doi.org/10.1016/j.amepre.2008.04.009

19. Guindon GE, Boisclair D. Past, current and future trends in tobacco use. UCSF: Center for Tobacco Control Research and Education 2003Retrieved from https://escholarship.org/uc/item/4q57d5vp.

20. Organization WH. WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco. 2011Available on: http://www.dejohoydefumar.gov.arwww.uata.org.ar/images/guias_concensos/9789240687813_eng_epidemia_de_tabaco_2011.pdf.

21. Organization WH. WHO report on the global tobacco epidemic, 2021: addressing new and emerging products. 2021Available on: https://iris.who.int/bitstream/handle/10665/343287/9789240032095-eng.pdf.

22. Quach BC, Bray MJ, Gaddis NC, Liu M, Palviainen T, Minica CC, et al. Expanding the genetic architecture of nicotine dependence and its shared genetics with multiple traits. Nature communications. 2020; 11(1): 5562. https://doi.org/10.1101/2020.01.15.898858

23. Organization WH. WHO global report on trends in prevalence of tobacco smoking 2015. 2015 Available on: https://iris.who.int/bitstream/handle/10665/156262/9789241564?sequence=1.

24. Organization WH. WHO global report on trends in prevalence of tobacco smoking 2000-2025. 2018Available on: https://iris.who.int/bitstream/handle/10665/330221/9789240000032-eng.pdf.

25. BPsyc TS, Anandan A, Lim CC, East K, Xu SS, Quah AC, et al. Global prevalence of heated tobacco product use, 2015‐2022: a systematic review and meta‐analysis. Addiction. 2023https://doi.org/10.1111/add.16199

26. Singh T, Arrazola RA, Corey CG, Husten CG, Neff LJ, Homa DM, et al. Tobacco use among middle and high school students—United States, 2011–2015. Morbidity and mortality weekly report. 2016; 65(14): 361-7. https://doi.org/10.15585/mmwr.mm6514a1

27. Hays JT, Ebbert JO, Sood A. Treating tobacco dependence in light of the 2008 US Department of Health and Human Services clinical practice guideline. Mayo Clinic Proceedings. 2009; 84(8): 730-6. https://doi.org/10.4065/84.8.730

28. Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clinical Pharmacology and Therapeutics. 2008; 83(4): 531-41. https://doi.org/10.1038/clpt.2008.3

29. Broms U. Nicotine Dependence and Smoking Behaviour: A genetic and epidemiological study. 2008 https://doi.org/10.4172/2155-6105.s2-0002

30. Hatsukami DK, Stead LF, Gupta PC. Tobacco addiction. The Lancet. 2008;371(9629):2027-38. https://doi.org/10.1016/s0140-6736(08)60871-5

31. Le Foll B, Piper ME, Fowler CD, Tonstad S, Bierut L, Lu L, et al. Tobacco and nicotine use. Nature Reviews Disease Primers. 2022;8(1):19. https://doi.org/10.1038/s41572-022-00346-w

32. Bonnie RJ, Stratton K, Kwan LY. The effects of tobacco use on health. Public Health Implications of Raising the Minimum Age of Legal Access to Tobacco Products. 2015https://doi.org/10.17226/18997

33. Peruga A, López MJ, Martinez C, Fernández E. Tobacco control policies in the 21st century: achievements and open challenges. Molecular oncology. 2021; 15(3): 744-52. https://doi.org/10.1002/1878-0261.12918/v1/review2

34. Chaloupka FJ, Yurekli A, Fong GT. Tobacco taxes as a tobacco control strategy. Tobacco Control. 2012; 21(2):172-80. https://doi.org/10.1136/tobaccocontrol-2011-050417

35. Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C, McRae TD, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA. 2015;313(7):687-94. https://doi.org/10.1016/j.jvs.2015.04.415

36. Leelavathi L. Nicotine Replacement Therapy for Smoking Cessation-An Overview. Indian Journal of Public Health Research & Development. 2019;10(11):1-8. https://doi.org/10.5958/0976-5506.2019.04144.5